THE ARISING · Longevity & Healthspan
An investigational drug reduced low blood sugar events after gastric bypass, sponsor reports
LUCIDITY’s 55% figure combines two levels of hypoglycemia. It does not mean 55% fewer patients had a severe episode.
For some people who have had Roux-en-Y gastric bypass, repeated drops in blood sugar make an ordinary meal or a day away from home unpredictable. Amylyx reported results from a trial of avexitide, an investigational drug being studied for post-bariatric hypoglycemia.
LUCIDITY randomized 78 adults with this condition to avexitide or placebo. The blinded comparison lasted 16 weeks, and both groups received usual dietary management for the condition. The primary measure was how often blood sugar fell to a specified low level or an adjudicated event was severe enough to require another person’s help.
Amylyx reported estimated weekly rates of 0.55 combined events on avexitide and 1.24 on placebo, a 55% lower event rate. This is a difference in repeated events, not the percentage of people who had any low, and not the effect on severe events alone. The sponsor reported a 47% reduction for adjudicated severe events in a separate secondary analysis.
The sponsor described adverse events as generally mild or moderate, mainly gastrointestinal or injection-site symptoms. It reported no deaths or treatment-related serious adverse events during the blinded period. With 78 participants and 16 weeks of blinded follow-up, uncommon and long-term harms remain uncertain.
These are sponsor-reported conference results for a specific complication after one type of surgery. The finding is a reason to look for the full peer-reviewed analysis and regulatory evaluation, not to assume the evidence applies to other forms of hypoglycemia or that the investigational drug is approved.